deCODE Reinstated to Nasdaq Global Market
26 Juin 2009 - 2:14PM
PR Newswire (US)
REYKJAVIK, Iceland, June 26 /PRNewswire-FirstCall/ -- deCODE
genetics (NASDAQ:DCGN) today announced that it has received notice
from the the Nasdaq Hearing and Listing Review Council that the
listing of the company's common stock will be reinstated to the
Nasdaq Global Market effective from the opening of trading on
Monday, June 29. deCODE's common stock will continue to trade under
the symbol DCGN. The reinstatement follows the Listing Council's
reversal of a decision in February by the Nasdaq Listing
Qualifications Panel under which the listing of deCODE's common
stock was transferred to the Nasdaq Capital Market. About deCODE
deCODE is a bio-pharmaceutical company developing drugs and
DNA-based tests to improve the treatment, diagnosis and prevention
of common diseases. Its lead therapeutic programs, which leverage
the company's expertise in chemistry and structural biology,
include DG041, an antiplatelet compound being developed for the
prevention of arterial thrombosis; DG051 and DG031, compounds
targeting the leukotriene pathway for the prevention of heart
attack; and DG071 and a platform for other PDE4 modulators with
therapeutic applications in Alzheimer's disease and other
conditions. deCODE is a global leader in human genetics, and has
identified key variations in the genome (SNPs) conferring increased
risk of major public health challenges from cardiovascular disease
to cancer. Based upon these discoveries deCODE has brought to
market a growing range of DNA-based tests for gauging risk and
empowering prevention of common diseases. Through its
CLIA-registered laboratory, deCODE offers deCODE T2(TM) for type 2
diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE
MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate
cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and
deCODE BreastCancer, for the common forms of breast cancer. deCODE
is delivering on the promise of the new genetics.SM Visit us on the
web at http://www.decode.com/; on our diagnostics site at
http://www.decodediagnostics.com/; for our pioneering personal
genome analysis service and new focused disease scans, integrating
the genetic variants included in these tests and those linked to
another twenty common diseases, as well as for our new deCODEme
Cardio(TM) and deCODEme Cancer(TM) scans, at
http://www.decodeme.com/; and on our blog at
http://www.decodeyou.com/. Any statements contained in this
presentation that relate to future plans, events or performance are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results, and the timing of events, to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, among others, those relating
to our ability to obtain sufficient financing to continue as a
going concern, our ability to develop and market diagnostic
products, the level of third party reimbursement for our products,
risks related to preclinical and clinical development of
pharmaceutical products, including the identification of compounds
and the completion of clinical trials, our ability to form
collaborative relationships, the effect of government regulation
and the regulatory approval processes, market acceptance, our
ability to obtain and protect intellectual property rights for our
products, dependence on collaborative relationships, the effect of
competitive products, industry trends and other risks identified in
deCODE's filings with the Securities and Exchange Commission,
including, without limitation, the risk factors identified in our
most recent Annual Report on Form 10-K and any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no
obligation to update or alter these forward-looking statements as a
result of new information, future events or otherwise. Contacts:
deCODE genetics Edward Farmer +44-7796-010107 Gisli Arnason
+354-570-1900 Joy Bessenger +1-212-481-3891 DATASOURCE: deCODE
genetics CONTACT: Contacts: deCODE genetics, Edward Farmer,
+44-7796-010107, ; Gisli Arnason, +354-570-1900, ; Joy Bessenger,
+1-212-481-3891,
Copyright